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Abstract
This study is designed to test the hypothesis that docetaxel [Doc] containing oily core nanocapsules [NCs] could
be successfully prepared with a high percentage encapsulation efficiency [EE%] and high drug loading. The oily
core NCs were generated according to the emulsion solvent diffusion method using neutral Labrafac CC and poly
(d, l-lactide) [PLA] as oily core and shell, respectively. The engineered NCs were characterized for particle mean
diameter, zeta potential, EE%, drug release kinetics, morphology, crystallinity, and cytotoxicity on the SUM 225
breast cancer cell line by dynamic light scattering, high performance liquid chromatography, electron microscopies,
powder X-ray diffraction, and lactate dehydrogenase bioassay. Typically, the formation of Doc-loaded, oily core,
polyester-based NCs was evidenced by spherical nanometric particles (115 to 582 nm) with a low polydispersity
index (< 0.05), high EE% (65% to 93%), high drug loading (up to 68.3%), and a smooth surface. Powder X-ray
diffraction analysis revealed that Doc was not present in a crystalline state because it was dissolved within the NCs’
oily core and the PLA shell. The drug/polymer interaction has been indeed thermodynamically explained using the
Flory-Huggins interaction parameters. Doc release kinetic data over 144 h fitted very well with the Higuchi model
(R
2 > 0.93), indicating that drug release occurred mainly by controlled diffusion. At the highest drug concentration
(5 μM), the Doc-loaded oily core NCs (as a reservoir nanosystem) enhanced the native drug cytotoxicity. These data
suggest that the oily core NCs are promising templates for controlled delivery of poorly water soluble
chemotherapeutic agents, such as Doc.
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Background
In cancer therapy, most of the proposed formulations
present certain drawbacks related to the formulation
properties including low drug loading, toxicity, and
unsuitable release pattern. An ideal formulation should
provide biocompatible nanosized particles and high drug
loading with sustained-release characteristics. This
allows releasing the drug in the target site in its thera-
peutic concentration and preventing drug inefficiency
and side effects. The current research was aimed to pre-
pare highly loaded docetaxel [Doc] oily core nanocap-
sules [NCs].
Doc, a semisynthetic analog of paclitaxel, is an extract
from the needles of the European yew tree Taxus bac-
cata [1]. It is prepared by chemical modification of 10-
deacetylbacattin III, an inactive precursor compound,
and then isolated [2]. Doc is a highly potent, cytotoxic,
and antimitotic agent used in the treatment of various
types of cancers, including metastatic breast, ovarian,
prostate, advanced non-small-cell lung, head/neck, and
advanced gastric cancers by inhibiting the microtubule
depolymerization of free tubulin [3,4]. Due to its poor
water solubility (10 to 20 μg/l), polysorbate 80 has been
markedly used to improve the aqueous solubility of Doc
[5-7]. This currently available, marketed formulation has
been associated with the absence of selectivity for target
tissues, serious dose limiting toxicities, and hypersensi-
tivity reactions, as well as sensory and motor neuropa-
thies that are sometimes severe and irreversible.
Previously, various alternative formulations, including
NCs, pegylated liposomes, targeted immunoliposomes,
Doc-fibrinogen-coated olive oil droplets, and cyclodex-
trins [8-15] have been intensively developed for the
delivery of Doc. However, the nanosized polymeric
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provided the original work is properly cited.nanoparticles represent promising drug-delivery systems
which have some advantages such as biodegradability,
good biocompatibility, non-toxicity, higher stability, and
controlled drug delivery. Polymeric nanoparticles (nano-
spheres and NCs) not only maintain a prolonged circu-
lation time in the body (especially when pegylated) by
avoiding the reticuloendothelial system, but also can
extravagate and accumulate into the tumor tissue. This
is likely due to the reliance of these nanoparticles on
passive accumulation through enhanced permeability
and retention, which is highly dependent on adequate
blood flow to the tumor [16].
According to the literature, the NCs correspond to
nanostructures with polymeric wall enveloping an oily
core, whereas the nanospheres consist of a polymeric
matrix [17]. There is increasing scientific evidence sup-
porting the notion that certain lipids are able to inhibit
both presystemic drug metabolism and P-glycoprotein-
mediated drug efflux [18]. Several polymers have been
proposed as nanocarriers for drug delivery systems. For
example, poly(d, l-lactic acid) and poly(ε-caprolactone)
[PCL] have been extensively used as nanocarriers
because of their excellent biocompatibility and biode-
gradability. These polyesters have been approved by the
US Food and Drug Administration and are the most
widely used commercial polymers for drug delivery
[19,20]. Presently, the only available Doc formulations
for clinical use consists of intravenous [IV] solutions
containing Tween 80
® (Sanofi-aventis, Bridgewater, NJ,
USA). These solutions namely Taxotere
® and Doce-
taxel
®, 10 to 20 mg/ml, are administered IV at a dose
ranging from 60 to 100 mg/m
2 over 1 h every 3 weeks
[21]). However, such high doses and a long term medi-
cation schedule may produce more severe side effects
[22]. One of the reasons could be ascribed to the com-
position of the formulation and the poor control of the
drug release rate. Therefore, the development of compa-
tible polymer-based nanocarriers with high drug loading
might be a helpful subject in cancer research.
The current research was aimed to prepare highly
l o a d e dD o co i l yc o r eN C s .H owever, the relationship
between drug and formulation excipients has also been
investigated to better control the encapsulation process.
Materials and methods
Materials
Poly(d, l-lactide) [PLA], Resomer
® R206, Mw 125 kDa,
with an inherent viscosity of 1.0 dl/g; PLA, Resomer
®
R207, Mw 209 kDa, with an inherent viscosity of 1.5 dl/
g; and PLA, Resomer
® R208, Mw 250 kDa, with an
inherent viscosity of 1.8 dl/g were purchased from Boeh-
ringer Inc. (Ridgefield, CT, USA). PCL (Mw = 72 kDa)
w a sk i n d l yp r o v i d e db yU n i o nC a r b i d e( D a n b u r y ,C T ,
USA). Polyvinyl alcohol [PVA] (9 to 10 kDa and 30 to
70 kDa) and ethyl acetate were obtained from Sigma-
Aldrich (St. Louis, MO, USA). Docetaxel or Doc was
purchased from LC Laboratories (Woburn, MA, USA).
Labrafac CC (caprylic/capric triglyceride, d = 0.945 g/
cm
3) was kindly supplied by Gattefosse Corporation (St-
Priest, France) as a gift. For the high-performance liquid
chromatography [HPLC] analysis, acetonitrile and
methanol were supplied from Fisher (Thermo Fisher
Scientific, Fair Lawn, NJ, USA). All the other reagents
were of analytical grade and used without further
purification.
Preparation of the nanocapsules
Experimental design and general procedure for Doc-loaded
nanocapsules
Fifteen formulations of Doc-loaded NCs were prepared
by emulsion-diffusion method as previously described
[19]. Briefly, the polyester (40 to 360 mg) was solubi-
lized in water-saturated ethyl acetate (10 ml); then, the
neutral oil (0.1 to 0.9 ml) containing Doc (2 to 18 mg)
was further added to the organic mixture. The resulting
solution was emulsified in 40 ml of PVA 2.5% to 5% (w/
v) aqueous phase solution by homogenization (homoge-
nizer, IKA ULTRA-TURRAX T-25, IKA Labortechnik,
Staufen, Germany) at 8,000 rpm for 10 min. A large
volume (200 ml) of deionized water was added dropwise
into the previous solution to promote the diffusion of
ethyl acetate into the aqueous phase. To remove the
organic solvent, the nanosuspension was stirred under
vacuum at 40°C Rotavapor
® R I I( B U C H IL a b o r t e c h n i k
AG, Flawil, Switzerland) for 30 min. NCs were recov-
ered by ultracentrifugation at 12,000 rpm at 5°C for 30
min, washed twice with deionized water to remove the
excess of PVA, and freeze-dried for 12 h (Labconco
Corp. Kansas City, MO, USA). Blank NCs were pre-
pared without Doc using the above method. The com-
position of the 15 formulations is listed in the first four
columns of Table S1 in Additional file 1.
Screening for polyester selection based on the blank
particle mean diameter
For the first screening test, a set of four biodegradable
polymers, including PLA R206, PLA R207, PLA R208,
and PCL, was used to obtain a suitable formulation
based on the mean diameter of the obtained blank NCs.
An amount of 200 mg of polyesters was solubilized in
an organic phase containing 10 ml of water-saturated
ethyl acetate and 0.5 ml of neutral oil. Each experiment
was performed in triplicate.
Screening for stabilizer selection based on the blank
particle mean diameter
S i n c eP V Ac o u l db eu s e da sa ne m u l s i o ns t a b i l i z e ri n
the NCs’ formulation process, it was important to first
investigate the effect of PVA molecular weight (9 to 10
kDa and 30 to 70 kDa) on the blank NCs’ mean
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tion (2.5% to 5%) on the particle mean diameter and
polydispersity index [PDI] was studied.
Physicochemical characterization of docetaxel-loaded
nanocapsules
Particles’ mean diameter and zeta potential analysis
The particle mean diameter and PDI of the Doc-loaded
NCs were measured by dynamic light scattering [DLS]
(Zetasizer Nano ZS series from Malvern Instruments
Ltd., Worcestershire, UK) as recently reported [23]. The
sample to be measured was appropriately diluted with
water and briefly sonicated for 2 min. The measurement
of each sample was completed at a scattering angle of
175°. Each measurement was done in triplicate, and the
average effective diameter and polydispersity were
recorded.
Drug loading and percent encapsulation efficiency of
docetaxel-loaded nanocapsules
The freeze-dried NCs (2 mg) were dissolved in 0.1 ml of
dichloromethane and diluted in methanol at the ratio of
1:14 v/v. After suitable dilutions, the amount of the
encapsulated Doc was determined by HPLC (Waters
Corporation, Milford, MA, USA) equipped with an UV
detector at 230 nm. Isocratic flow of the mobile phase,
composed of methanol/water/acetonitrile (30:30:40 v/v/
v), was employed at a flow rate of 1.0 ml·min
-1 with a
10-μl injection volume. Doc separation was completed
using an XBridge™ column C-18, at 4.6 × 150 mm and
3.5 μm (Waters Corporation, Milford, Massachusetts).
The experimental Doc loading was quantified using the
peak area of each NC formulation. Drug loading [DL]
and percent encapsulation efficiency [EE%] were calcu-
lated according to Equations 1 and 2, respectively:
DL =
Drug amount
Polymer amount + drug amount
× 100% (1)
EE =
Experimental drug loading
Theoretical drug loading
× 100% (2)
Scanning electron microscopy analysis
Scanning electron microscopy [SEM] was used to assess
the NCs’ morphology. A droplet of NCs’ suspension was
put into a grid. The excess of the fluid was removed by
wicking it off with an adsorbent paper, and then, it was
visualized under a Hitachi S4700 cold-cathode field
emission SEM [FESEM] (Hitachi High-Technologies
Corporation, Minato-ku, Tokyo, Japan). The particles
were sprinkled onto a stub covered with an adhesive
conductive carbon tab, then sputter-coated with a fine
layer of platinum metal. Then, the particles were imaged
in the FESEM at 2 to 5 kV.
Transmission electron microscopy analysis
The selected samples were examined with a JEOL 1400
transmission electron microscope [TEM] (JEOL Ltd.,
Tokyo, Japan) and photographed digitally on a Gatan
axis-mount 2 k × 2 k digital camera (Gatan, Inc., Plea-
santon, CA, USA). The freeze-dried samples were put
into a small mold, referred to as a BEEM capsule, and
then imbedded in liquid epoxy resin (Epon-Araldite,
Sigma-Aldrich Corporation, St. Louis, MO, USA). The
resin was polymerized at 60°C for 2 days, and then,
ultrathin 80-nm sections were cut on a Leica UCT
ultramicrotome (Leica Microsystems Ltd., Milton Key-
nes, UK) with a Diatome diamond knife (Diatome, Hat-
field, PA, USA). The sections were collected on 200-
mesh copper grids and put into the TEM for imaging
on a Gatan digital camera.
Powder X-ray diffraction pattern analysis
Powder X-ray diffraction [PXRD] analysis of the freeze-
dried NCs was performed using a MiniFlex automated
X-ray diffractometer (Rigaku, The Woodlands, TX,
USA) at room temperature. Ni-filtered Cu Ka radiation
was used at 30 kV and 15 mA. The diffraction angle
covered from 2θ =5 °t o2 θ = 60°, with a step size of
0.05°/step and a count time of 3 s/step (effectively 1°/
min). The diffraction patterns were processed using Jade
8+ software (Materials Data, Inc., Livermore, CA, USA).
Refractive index measurement
The oil, water-saturated ethyl acetate, and ethyl acetate-
saturated water refractive index values were measured
experimentally at 25°C (Auto Abbe 10500 Refract-
ometer; Reichert Analytical Instruments, Depew, NY,
USA) using Milli-Q water (Millipore Co., Billerica, MA,
USA) as a reference. A droplet of liquid was deposited
on the prism surface. The obtained values are the aver-
age of five measurements.
In vitro drug release kinetics
This experiment was performed using the equilibrium
dialysis method for 144 h. Specifically, a known amount
of Doc-loaded oily core NCs (1 mg) was suspended in a
dialysis bag (Spectra/Float-A-Lyzer, MWCO 3.5-5 kDa,
Spectrum Laboratories Inc. Rancho Dominguez, CA,
USA) containing 5 ml of phosphate buffer saline [PBS]
(Sigma-Aldrich, St. Louis, MO, USA). The bag contain-
ing the NCs’ suspension was placed in 40 ml of PBS.
The system was placed in a shaking water bath (BS-06,
Lab. Companion, Des Plaines, IL, USA) at 37°C with an
agitation speed of 50 rpm. At predetermined time inter-
vals, 500 μlo fP B Ss o l u t i o nw a sw ithdrawn from the
immersion medium and replaced by the same volume of
fresh medium. The cumulative percentage of drug
released for each time point was calculated as a percen-
tage of the total drug loading of the NCs tested. The
quantitative analysis of the data obtained from the study
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elucidate the mechanism of the drug release.
Solubility parameter determination
To predict the compatibility between the Doc (solubili-
zate) and polymer (solvent), the Flory-Huggins solubility
parameter was evaluated [csp]. Our goal was to deter-
mine the interaction parameter csp [25] using the ther-
modynamic approach based on the extended Hildebrand
solubility. According to Hildebrand, the solubility para-
meter [δ], defined as the square root of the cohesive
energy density [CED], is equal to the energy of vaporiza-
tion ΔEv per unit of molar volume (Equation 3) [26].
The solubility parameter is used to calculate csp using
Equation 3:
δ = (CED)
1/2 =

 Ev/Vm
1/2 (3)
Hansen modified the Hildebrand approach and
divided δ into three components that take into account
the force of the dispersion [δd], the polarity [δp], and the
hydrogen bonds [δh]. Therefore, δ is calculated using
Equation 4:
δ2
t = δ2
d + δ2
p + δ2
h (4)
Equation 5 below was used to estimate the total Hil-
debrand solubility parameter based on the refractive
index [nD], where δt was the Hildebrand solubility para-
meter in (cal/cm
3)
1/2, and 304.5 was an empirically
determined constant [27]. The refractometer was cali-
brated using pure water according to the instrument
manual. Then, the total solubility parameter was calcu-
lated by using Equation 5:
δt =

304.5

n2
D − 1
n2
D +2

(5)
An interaction parameter with a value smaller than 0.5
(i.e., csp < 0.5) indicates that the solvent polymers are
compatible. The interaction parameter can be calculated
from the solubility parameters [28]. Considering the cor-
responding δt for each component, the value of the
interaction parameter (csp) can be estimated from the
Hildebrand solubility parameters δs and δp (for solubili-
sant and polymer, respectively). On the basis of regular
solution theory, the relationship between the Flory-Hug-
gins interaction parameter and the solubility parameter
is defined by using Equation 6:
χsp =

δs − δp
2. Vm/R.T (6)
where Vm is the molar volume of the drug, R is the
ideal gas constant (8.314 J·K
-1·mol
-1), and T is the tem-
perature in Kelvin (293.15 K) [29].
In vitro evaluation of Doc-loaded nanocapsules’ cytotoxicity
The NCs’ cytotoxicity was evaluated using the SUM 225
cell line (Asterand, Inc., Detroit, MI, USA). The cyto-
toxicity after treatment of these cells with native Doc
and Doc-loaded NCs at different equivalent drug con-
centrations (1 nM, 2.5 μM, and 5 μM) was evaluated by
the lactate dehydrogenase [LDH] assay. The cells were
plated at a density of 5 × 10
3 cells per well for 24 h in
96-well plates in a standard growth medium prior to
exposure to the above materials. Blank NCs, and med-
ium containing 0.5% dimethyl sulfoxide [DMSO] are
used as negative controls, while Triton-X 1% (Sigma-
Aldrich Corporation, St. Louis, MO) was used as a posi-
tive control and incubated for 24 h at 37°C in 5% CO2.
After the treatment, the LDH reagents were used
according to the manufacturer’s instruction (Promega
Life Sciences, Madison, WI, USA). The experimental
results were expressed as mean values of six measure-
ments (n = 6), and the cytotoxicity was calculated by
the following formula:
Cytotoxicity (%)=
Experimental − Background
Positive − Background
× 100 (7)
where, experimental, background, and positive repre-
sent the fluorescence intensity of NC-treated wells,
background wells (wells without cells), and positive con-
trol wells (cells treated with 1% of Triton X-100),
respectively. The fluorescence intensity was detected by
using a microplate reader (DTX 800 multimode micro-
plate reader, Beckman Coulter, Brea, CA, USA) at an
excitation wavelength of 560 nm and emission wave-
length of 590 nm.
Results and discussion
Polymer selection based on the mean diameter of blank
nanocapsules
This experiment was performed to find out the suitable
polymer using small-sized NCs. Four polymers were
initially screened including PLA R206, PLA R207, PLA
R208, and PCL. Figure 1 shows the effect of different
biodegradable polymers on the average diameter of
blank NCs. The NCs’ mean diameters were 127.5 ± 19.2
nm for NC-PLA206, 123.8 ± 0.9 nm for NC-PLA207,
110.8 ± 8.6 nm for NC-PLA208, and 124.6 ± 3.1 nm for
NC-PCL. These findings indicated a statistically signifi-
cant decrease of PLA NCs’ diameters with increasing
polymer molecular weights (P < 0.003, T test). Based on
their smaller mean diameter, the NCs prepared with
PLA R208 were selected for the subsequent studies. The
results did not show any difference regarding the zeta
potential values (ζ =- 3 6 . 5±9m V )a m o n gt h eb a t c h e s
of NCs (data not shown). This high potential value also
contributed to the stabilization of the nanosuspension.
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the blank particle mean diameter
This preliminary experiment was performed to select
the accurate PVA molecular weight and concentration
with the goal of minimizing the particle size. Figure 2A,
B, C, D shows that the NCs’ mean diameter decreased
with increasing both the PVA’s molecular weight (9 to
10 kDa, to 30 to 70 kDa) and concentration (2.5% to
5%, w/w). Oppositely, previous studies have pointed out
the increase of the PLGA NP mean diameter when the
concentration of PVA was increased from 2% to 6%
[30]. This effect was attributed to the increase of the
external phase viscosity, which decreases the molecular
diffusion rate and Ostwald ripening phenomenon. This
revealed that the PVA concentration is not the only
parameter governing the particle mean diameter.
According to the overall results, PLA 208 and PVA (30
to 70 kDa, 5%) were finally selected for the following
NC preparation.
Preparation and characterization of docetaxel-loaded
nanocapsules
For optimization purposes, 15 batches of PLA R208
Doc-loaded oily core NCs were prepared using the
above method. As shown in Table S1 in Additional file
1, the lowest value of the NCs’ diameter was obtained
with F6 (115.6 nm), while the largest particle diameter
was obtained with F9 (582.8 nm). The PDI ranged from
0.004 to 0.318 (F14 and F9, respectively). It was found
that the particle mean diameter is strongly dependent to
the polymer amount. Indeed, at a low PLA amount (40
mg), the particle mean diameter increases with increas-
i n gd r u ga m o u n t( s e eF 9 versus F10, P < 0.0001). This
might be explained by the fact that the lipophilic feature
tends to decrease the leakage of the drug into the exter-
nal aqueous medium, leading to improved drug content
in the nanoparticles (which is consistent with the pre-
vious report) [19]. However, at a high PLA amount (360
mg), the particle mean diameter decreases with increas-
ing drug amount (see F4 versus F5, P < 0.0001). The lat-
ter was not consistent with the commonly published
report and might be a result of drug solubilization in
the polymer matrix, leading to decrease the particle
mean diameter. Thus, the solubilization capacity of PLA
has a great importance in the preparation of the Doc-
loaded NCs.
From Table S1 in Additional file 1, the data suggest
that the NCs’ mean diameter decreases with increasing
oil content from 189 nm to 133 nm (see F3 versus F13,
P < 0.0001). The results also show that at a low oil con-
tent, the drug level did not have any effect on the NCs’
mean diameter, which is consistent with the previous
study [31].
From Table S1 in Additional file 1, it appears that for
most of the formulations, the PDI value was less than
0.05, indicating a monodispersity according to the
Figure 1 Influence of the nature of biodegradable polyester on blank oily core nanocapsules mean diameter. n =3 ;S . D . :s t a n d a r d
deviation between the three assays: PLA206 (105 kDa), PLA207 (209 kDa), PLA208 (250 kDa), and PCL (72 kDa).
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dispersity seems to be increased with decreasing PLA
amount (see F13 versus F1, from 0.005 to 0.296, P =
0.0078). This suggests that the PLA amount may contri-
bute to ensure the NCs’ monodispersity.
Table S1 in Additional file 1 lists also the EE% of the
Doc-loaded NCs. Interestingly enough, the results
showed that the EE% was mainly governed by the PLA
content. A high PLA content led to a high EE% (see
pairwise comparison: F1 to F13,F 3 to F9,F 4 to F11,F 5 to
F10, respectively). At a low PLA content, the EE% was
decreasing regardless of the oil content (comparing F9
to F10, P = 0.0006). At a high oil content, a medium
content of PLA is at least required to obtain a high EE%
(see F7 and F13, P = 0.9038). The lowest EE% (F9, 65.3%)
was obtained when the PLA and oil contents were both
at the lowest level (40 mg and 0.1 ml, respectively). This
is because the encapsulation process of hydrophobic
drugs into these particles results from the interaction
between the drug, polymers, and oil. Thus, the drug
loading and EE% were found to depend on its solubility
in the polymeric material, which is strongly related to
the polymer composition, its molecular weight, the drug
and polymer interaction, and the presence of end-func-
tional ester or carboxyl groups [31]. These findings were
consistent with a previous report [19]. Once the NCs’
physicochemical properties have been analyzed, their
size and morphology can be most directly monitored by
various forms of electron microscopy.
Physicochemical characterization of docetaxel-loaded
nanocapsules
Morphological analysis
The particle mean diameter and morphology were ana-
lyzed by SEM and TEM. Figure 3 shows a typical SEM
picture of spherical NCs with smooth surfaces and
undetectable free drug crystals. The NCs’ size as esti-
mated by SEM correlated well with the size measured
by the DLS showing particles in a nanometric size
range. The TEM analysis shows clearly a white and
Figure 2 Influence of PVA concentrations (A, B) and molecular weights (C, D) on the blank NC mean diameter. This is detected by DLS
(n = 3; S.D.: standard deviation between the three assays).
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Figure 4 Transmission electron micrographs of PLA 208 oily core nanocapsules after freeze drying (F6). Scale bar represents 0.2 μm.
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ure 4). Therefore, it is necessary to investigate the drug
structure inside the NCs.
Powder X-ray diffraction analysis
This experiment aimed to characterize the crystallinity
of Doc in the formulated NCs. Figure 5 shows the
PXRD results of the formulations containing different
amounts of Doc (F6,F 12,a n dF 13) and the individual
native chemical compounds used in the tested formula-
tions. The native Doc exhibited sharp and characteristic
diffraction peaks at 8.72°, 10.28°, and 11.7°, which is
consistent with a previous report [34]. The Doc crystals
are orthorhombic. The unit cell parameters (at room
temperature) are a = 39.9345 Å, b = 12.7749 Å, c =
8.6644 Å, with V = 4420.2 Å. The number of motifs (Z)
per cell is 4, and the density of the crystal is 1.295 [35].
The native PLA is characterized by a broad diffraction
peak, which was centered at 25°. The PXRD pattern of
the native PVA shows a broad lump between 17° and
20° both in the native component and in the tested for-
mulations, which suggests that the PVA molecule is pre-
sent in the NCs. The previous study indicated that the
OH groups of PVA was adsorbed on the surface of the
NCs and can keep the NCs in a pseudo-hydrated state
[36]. The diffraction patterns of the native PLA exhibit a
broad diffraction peak from 2θ =1 6 . 7 °t o2 θ =3 5 ° .
These results indicate that Doc is not present as a crys-
talline state, but is probably dissolved within the NCs’
core and shell while some residual PVA might be pre-
sent on the surface of the NCs.
In vitro drug release study
The purpose of this study was to investigate the drug
release mechanisms from Doc-loaded NCs. The cumula-
tive percentages of Doc released from NCs as a function
of time are reported in Figure 6. The results indicate
that the drug release rate depends on the NCs’ proper-
ties. The Doc oily core NCs were characterized by a sus-
tained release profile (less than 40% of Doc is released
within 60 h). This might be attributed to the hydropho-
bic interaction between the hydrophobic moiety of PLA,
oil, and Doc. Compared to a previous result using nano-
sphere-based PLA [37], one can assume that the drug
release is mainly due to the oil contained inside the
NCs’ core. The release data of Doc from the NCs (Fig-
ure 6) were fitted to the Higuchi model [38] to deter-
mine the drug release mechanism. The drug release
constant (k) and regression coefficient (R
2) of the Higu-
chi model are shown in Table S2 in Additional file 1.
Accordingly, the Doc release was best supported by
Higuchi’s model, i.e., based on Fickian diffusion, as it
presented the highest values of linearity (R
2 >0 . 9 3 )f o r
all formulations. From F6, the release rate of Doc in 24
h corresponds to 0.9 nmol. This concentration is consis-
tent with a previous report where the EC50 of Doc was
ranged from 1 to 6.2 nmol. [39]. In these conditions, the
low drug level in simulated plasma pH suggests that a
Figure 5 PXRD pattern.A ,n a t i v eD o c ;B ,F 13 (PLA, 360 mg; Doc, 10 mg; oil, 0.9 ml); C, F12 (200 mg, 10 mg, 0.5 ml); D, F6 (200 mg, 18 mg, 0.9
ml); E, blank nanocapsules; F, native PVA; and G, native PLA 208.
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drug release in situ within the targeted cancer cells in
order to spare vital organs and significantly reduce the
unwanted systemic side effect. To better understand the
compatibility between Doc and PLA, as well as the neu-
tral oil, the Flory-Huggins interaction parameter calcula-
tions were carried out as shown below.
Solubility parameter determination
To prove the suitability of PLA and oil for the optimal
solubilization of Doc in the nanostructure, the Flory-
Huggins interaction parameters were computed. The
solubility parameters of Doc (δs) and PLA (δp)w e r ec a l -
culated and listed in Table S3 in Additional file 1.
According to the Flory-Huggins theory, the critical csp
value above which a polymer and a low molecular
weight compound (i.e., drug) become miscible is < 0.5.
Therefore, a lower value of csp should result in a higher
solubility. The obtained interaction parameters (csp)
between Doc and PLA and between Doc and oil were
calculated. Table S3 in Additional file 1 shows a low
value of the interaction parameter (csp) between Doc
and PLA 0.65 (cal/cm
3)
1/2. In contrast, the interaction
solubility value between Doc/oil was relatively high 1.64
(cal/cm
3)
1/2, indicating that Doc is more compatible
with PLA than with the oil. This finding seems to show
that a high PLA content may contribute to high drug
EE% (up to 93%). To confirm the suitability of the oil/
ethyl acetate mixture (phase A) with water (phase B) for
the NCs’ formation, the interfacial tension (gAB) between
these two immiscible phases (A and B) was predicted by
Kim and Burgess [40] using Equation 7:
γAB = γA − γB exp

−αV0.7
+ γB (7:1)
where gAand gB (72 mN/m at 25°C) are the surface
tension of each phase (A or B), a is an exponential coef-
ficient, and V is the volume fraction of the oil mixture.
The a-value can be calculated by using the following
equation:
α = 0.178 ( γ) − 0.0132 (8)
where Δg is the surface tension difference between
ethyl acetate and oil, respectively.
The surface tensions of pure oil and ethyl acetate are
30.00 mN/m [41] and 6.80 mN/m [42], respectively. The
Δg resulting from mixing these two substances is 23.20
mN/m, which is estimated to be gA. From Equation 8, a
was found to be 4.10 mN/m. However, the obtained
value of gAB from Equation 7 was 7.94 mN/m.
It is important to bear in mind that the interfacial ten-
sion of the oil/water system could be altered when
another organic liquid is added to the oil phase, result-
ing in a compositional change at the interface and
hence changes in the cohesive and adhesive forces [40].
On the basis of the above result, it is useful to rationa-
lize whether or not the oil droplet entrapment/engulfing
Figure 6 Cumulative drug release from Doc-loaded nanocapsules in PBS (pH 7.4), at 37 ± 0.5°C. Each point represents the mean value of
three different experiments ± standard deviation.
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Page 9 of 12inside the polymer shell can occur. To be effective, this
should normally occur before the solvent diffusion step,
where the polymer forming the shell is in a liquid state.
To achieve this goal, the oil droplet inclusion within the
polymer shell has been predicted using the interfacial
tension between the three phases, A, B, and C, and the
spreading coefficients as defined [43,44]:
SA = γBC − (γAB + γAC) (9)
SB = γCA − (γBC + γBA) (10)
Sc = γAB − (γCB + γCA) (11)
where g is the interfacial tension (A, B, and C refer to
the three phases). Based on these conventions, complete
engulfing of phase A by phase C will occur if only if SA <
0, SB <0a n dSc > 0. In this study, oil-ethyl acetate mix-
ture is the phase A, water is phase B, and the polymeric
phase (PLA) is phase C. The calculation of the spreading
coefficients of a specific phase A/phase C system allows
predicting the possible formation of oily core NCs.
The corresponding interfacial tension values were
obtained as follows: gBC was obtained from the literature
(gBC = +6.83 mN/m [45], gAC = +0.06 mN/m was
obtained from Table S4 in Additional file 1[46,47], and
gAB calculated from Equation 7 was 7.94 mN/m, which
is comparable to the literature value of 8.42 mN/m [45].
The positive sign of the water-PLA interfacial tension
(gBC = +6.83 mN/m) implies that it tries to reduce its
energy by reducing its surface area, and therefore, a
spherical shape might be maintained. Based on these
data, the obtained spreading coefficients were SA = -1.17
mN/m (< 0), SB =- 1 4 . 7 1m N / m( <0 ) ,a n dSC = +1.05
mN/m (> 0). Thermodynamically, the driving forces
allowed the formation of a PLA layer between the water
and oily phase, thus engulfing the oily phase. These data
fundamentally explain why the oily core was surrounded
by a polymer layer as visually evidenced by the TEM
analysis.
In vitro evaluation of Doc-loaded NC cytotoxicity
Figure 7 shows the cytotoxicity from the LDH assay of
native Doc and Doc-loaded NCs at three tested different
concentrations. The cell culture medium used as a nega-
tive control was not cytotoxic. At lower concentrations,
the native drug appeared more bioactive perhaps due to
rapid diffusion and higher level of interaction with the
cells. However, at the highest concentration (5 μM), the
drug-loaded NCs’ cytotoxicity was significantly higher
than that of the native Doc. This data clearly suggests
that the oily core NC formulation (as a reservoir system
for the drug) could enhance the biological responses of
the native Doc with higher drug payload. This might be
due to the sustained release properties of the NCs and
the enhanced drug internalization by SUM 225 cells in
the nanocapsule form. This observation was consistent
Figure 7 Percent SUM 225 cell death by LDH assay after different treatments for 24 h. See text for details. Pairwise comparison: native
drug versus drug loaded NCs at the same concentration. Data are expressed as mean percent ± SD from six measurements (n = 6).
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Page 10 of 12with a previous report [48] related to a nanoparticulate
form of another anticancer drug (doxorubicin) tested on
a different breast cancer cell line (MCF7).
Conclusions
In this work, we developed PLA-based Doc-loaded oily
NCs by solvent diffusion method. The results confirmed
the formation of Doc-loaded oily core polyester-shell
NCs in the nanosize range (115 to 582 nm) and high EE
% (65% to 93%). Most of the NCs were monodisperse in
size (PDI = 0.005) with smooth surface. The PXRD data
suggested that Doc was dissolved in the NCs. The Doc
release data over 144 h fitted well with the Higuchi
model (R
2 > 0.93), indicating that the drug mainly dif-
fused out of the NCs in this timeframe. Consistent with
the analysis of the spreading coefficients and visual evi-
dence from EM, the NCs’ oily core was indeed formed.
The results from the cytotoxicity study suggested that at
a high concentration (5 μM), the enhanced toxicity of
the encapsulated drug on the examined cancerous cell
line might be due to both the particle’s uptake by the
SUM 225 cells and the sustained drug release profile
from the NCs. In a future work, we plan to investigate
the cancer cell targeting capability of pegylated Doc-
loaded NCs conjugated to specific ligands for drug
delivery applications.
Additional material
Additional file 1: Supplementary tables. Four supplementary tables
showing the physicochemical characteristics of the Doc-loaded oily core
nanocapsules (n = 3), key parameters resulting from fitting the Doc
release profile to the Higuchi model, physicochemical properties of drug
and excipients, and physicochemical properties and surface tension of
drug and excipients, respectively.
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